SCHEDULE 13G: Affinity Healthcare Fund Discloses 5.7% Stake in Ventyx Biosciences
Beneficial Ownership Disclosure
Affinity Healthcare Fund, LP and its investment manager, Affinity Asset Advisors, LLC, have reported a 5.70% beneficial ownership stake in Ventyx Biosciences, Inc. through a Schedule 13G filing.
Summary
- Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have filed a Schedule 13G with the SEC, disclosing their beneficial ownership in Ventyx Biosciences, Inc.
- The reporting persons collectively beneficially own 4,057,105 shares of Ventyx Biosciences, Inc. Common Stock.
- This ownership represents 5.70% of the outstanding shares of Ventyx Biosciences, Inc. Common Stock.
- Affinity Asset Advisors, LLC acts as the investment manager for Affinity Healthcare Fund, LP and exercises investment discretion over the reported securities.
- Both Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC share voting and dispositive power over the 4,057,105 shares.
- The percentage of class is calculated based on 71,161,201 shares of Common Stock outstanding as of May 5, 2025, as reported in Ventyx Biosciences' Quarterly Report on Form 10-Q filed on May 8, 2025.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment beyond the fact of an institutional investment.
Positives
- The disclosure of a significant institutional investment by Affinity Healthcare Fund, LP, holding 5.70% of Ventyx Biosciences, Inc., may signal confidence from a specialized healthcare investor in the company's prospects.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment stance rather than an activist one.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Ventyx Biosciences, Inc., a company operating in the healthcare/biotechnology sector. Such disclosures are common for passive investments by funds in publicly traded companies, reflecting an investor's position rather than specific operational or strategic updates from the company itself.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which may be viewed as a positive signal of investor interest in Ventyx Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 05/05/2025 | Date as of which 71,161,201 shares of Ventyx Biosciences, Inc. Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 05/08/2025 | Date Ventyx Biosciences, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 05/22/2025 | Date of the event which required the filing of this Schedule 13G statement. |
| 05/30/2025 | Date the Schedule 13G statement was signed by Andrew Weinstein on behalf of both reporting persons. |
Keywords
Ventyx Biosciences, Affinity Healthcare Fund, Affinity Asset Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.